Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

T Cell Types and Functions

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

Inflammatory Bowel Disease III: Crohn's Disease

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

Inflammatory Response

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

EPS and iPS Cells in Disease Research

EPS and iPS Cells in Disease Research

Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Frailty in End-Stage Renal Disease Patients under Dialysis and Its Association with Clinical and Biochemical Markers.

The Journal of frailty & aging·2017

Same author

Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study.

The British journal of dermatology·2017

Same author

Non-surgical treatments for hidradenitis suppurativa: A systematic review.

Annales de chirurgie plastique et esthetique·2017

Same author

Recurrent epistaxis: predicting risk of 30-day readmission, derivation and validation of RHINO-ooze score.

Rhinology·2017

Same author

Systemic treatment of severe adult Atopic dermatitis in clinical practice: analysis of prescribing pattern in a cohort of 241 patients.

Journal of the European Academy of Dermatology and Venereology : JEADV·2017

Same author

Authorship selection in industry-sponsored publications of dermatology clinical trials.

The British journal of dermatology·2017

Search research articles

Related Experiment Video

Updated: May 21, 2026

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Published on: September 26, 2013

Psoriasis: rationale for targeting interleukin-17.

G Girolomoni¹, U Mrowietz, C Paul

¹Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.

The British Journal of Dermatology

|June 22, 2012

Summary

This summary is machine-generated.

Interleukin-17A (IL-17A) is crucial in plaque psoriasis development. Blocking IL-17A shows promise for treating this chronic skin condition by targeting immune dysregulation.

Related Experiment Videos

Last Updated: May 21, 2026

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Published on: September 26, 2013

Area of Science:

Immunodermatology
Cytokine Biology
Psoriasis Pathogenesis

Background:

Plaque psoriasis pathogenesis involves genetic and environmental factors triggering immune responses.
The cytokine interleukin-17A (IL-17A) is vital for host defense but also implicated in psoriasis.
IL-17A is produced by various immune cells found in psoriatic lesions, including Th17 cells, neutrophils, and mast cells.

Purpose of the Study:

To investigate the role of IL-17A in plaque psoriasis.
To evaluate the therapeutic potential of targeting IL-17A in psoriasis treatment.

Main Methods:

Review of existing evidence on IL-17A's role in psoriasis.
Analysis of experimental models and clinical trial data for IL-17 inhibitors.
Examination of IL-17A's effects on keratinocytes and immune cell recruitment.

Main Results:

IL-17A promotes inflammation by increasing chemokine expression and recruiting immune cells to psoriatic lesions.
Blocking IL-17A demonstrated efficacy in experimental models of psoriasis-like pathology.
Clinical trials of IL-17 inhibitors showed significant reductions in disease severity for moderate-to-severe plaque psoriasis.

Conclusions:

IL-17A is a key driver of plaque psoriasis pathophysiology.
Targeting IL-17A represents a promising therapeutic strategy for selective intervention in psoriasis.
IL-17 inhibitors have shown significant clinical benefit in patients with moderate-to-severe plaque psoriasis.